cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Anterior Repositioning Guided Splint Combined With or Without I Platelet-rich Fibrin

The study aims to evaluate clinically and radiographically the effectiveness of arthrocentesis and injection of I-PRF with wearing ARS in comparison to arthrocentesis and ARS only.

The patient will be seated at a 45° angle with the head turned toward the unaffected side. After preparing and disinfecting the target site with betadine, two points will be marked over the affected joint. Local anesthesia will be administered to block the auriculotemporal nerve. Using 19-gauge needles, the superior joint space will be distended with 2-3 ml of Ringer's solution. Another needle will be inserted into the distended compartment near the articular eminence to facilitate solution flow. Lactated Ringer's solution, connected to one needle, will be infused with sufficient pressure (200 mL in 15-20 minutes) to release adhesions. Following the removal of one needle, 2 ml of injectable platelet-rich fibrin (PRF) will be injected into the superior joint space.

For the preparation of injectable PRF, 20 ml of the patient's blood will be drawn and divided into two 10 ml vaccutainers. After centrifugation, the obtained PRF will be aspirated into a 5 ml syringe, and 1.5 to 2 ml of PRF will be injected into the superior joint space.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 years and older.
* History of unilateral or bilateral disc displacement without reduction (DDwoR) of the temporomandibular joint (TMJ) confirmed by MRI.
* Presence of TMJ pain and restricted maximum mouth opening.
* No improvement with conservative treatment.
* Absence of MRI contraindications.

Exclusion Criteria:

* Patients having any systemic disease that could interfere with the TMJ treatment or assessment.
* Patients having previous TMD treatment modalities or previous TMJ surgery.
* Patients with a previous history of oral and or maxillofacial trauma.
* Patients that are contraindicated to perform MRI.
* Completely or partially edentulous patients were also excluded.
Study of Calcium Metabolism in Teenage Girls With Type 1 Diabetes

The proposed pilot study will enroll 33 adolescent females with type 1 diabetes for the assessment of whole body calcium metabolism using dual stable calcium isotopes. This is the state of the art technique for assessing calcium metabolism in the body and has been used in both healthy and diseased pediatric populations.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of T1D of at least three years duration
* Female sex
* Age between 9-18 years
* Parental/guardian consent and participant assent
* BMI \<99th percentile

Exclusion Criteria:

* History of metabolic bone disease, chronic renal disease, hepatic disease, celiac, or other malabsorptive disease
* History of any proton-pump inhibitor use within a 6 month period prior to enrollment
* History of oral or inhaled corticosteroid use for ≥ 5 consecutive days within a 6 month period prior to enrollment
* Pregnant or lactating females
* Parents/guardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.


Eligibility Criteria:
Inclusion Criteria:

* Hypertension (2 grade)

Exclusion Criteria:

* Secondary hypertension
* Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
* Pregnancy
AA Linkage for Alcohol Abusing Women Leaving Jail

The primary aims of this study are to test the hypotheses that among alcohol abusing and dependent jailed women returning to the community, adding an Alcoholic Anonymous (AA) linkage intervention will result in less alcohol use at follow-up, increased AA attendance once released, and decreased HIV/STI sexual risk behavior. Additionally, this study seeks to test the hypotheses that increased AA attendance will mediate the effect of the AA linkage intervention on alcohol use and that percent days abstinent will mediate the effect of the intervention on HIV/STI sexual risk-taking outcomes.


Eligibility Criteria:
Inclusion Criteria:

To be eligible for the study participants must:

1. Be 18 years or older
2. Live in RI or MA within 20 miles of Providence and plan to remain in the area for the next 6 months
3. Meet DSM-IV criteria for alcohol abuse or dependence in the last six months
4. Do not expect to attend residential alcohol or drug treatment upon release
5. Report STI/HIV sexual risk defined as unprotected heterosexual sex at least three times in the three months prior to incarceration
6. Speak English.
7. Be currently held at the Rhode Island Adult Correctional Institutions Jail facility

Women will be excluded from participation if they:

1. Cannot provide the name of at least two locator persons who will know where they can be found.
European Organisation of Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ) Breast Cancer Module Update

The purpose of this study is to update the EORTC QLQ Breast (BR)-23 Module. Since the development of BR-23 published 1996 the standard therapy of breast cancer has changed. New therapies brought new side effects and different impact on QoL (quality of life) are not sufficiently covered by EORTC QLQ BR-23 and an update of the module could be useful, both from clinical and scientific point of view.

1. Based on a systematic literature search a new issue list will be developed, containing additional issues relevant for new treatment strategies. A total of 5-10 patients from different countries (5-8) as well as health care professionals (5/country) will be interviewed (Phase 1).
2. Operationalization of the issues into items; a provisional version of a the questionnaire and a hypothetic scale structure will be established (Phase2).
3. The resulting provisional updated module will be tested with respect to understanding, comprehensiveness and applicability (according to the EORTC Module Development Guidelines). The items will be translated from English into other languages following a standardized forward-backward procedure. Total aof 260 patients will be interviewed from different cultural areas: Northern Europe, Central Europe, Southern Europe, Asia (Phase 3).
4. The module and its scale structure will be field-tested in a large, international group of patients in order to determine its acceptability, reliability, validity, responsiveness and crosscultural applicability .

Eligibility Criteria:
Inclusion Criteria:

* Patients with early or metastatic breast cancer

Exclusion Criteria:

* Patients with second malignancy
Intravenous Ketamine Effects on Functional Neuroanatomy

The purpose of this study is to investigate the neuroanatomical effects of ketamine treatment on patients with treatment-resistant depression. The investigators will compare the neuroimaging of patients several days before and after injection in order to assess the more durable changes induced by ketamine. In addition, changes in perfusion will be analyzed, in addition to changes in neurovascular coupling, and functional connectivity that are correlated with psychiatric measures.

The present study is designed as a prospective data analysis of patient response to the use of ketamine to treat treatment-resistant depression. For Phase I trail, 10 patients of any gender with an age range of 18 to 70 who have undergone the outlined procedure will be recruited for inclusion. Patients will be examined by the principle investigator. All patients must be diagnosed with persistent treatment-resistant depression and prescribed ketamine. Patients will be accepted regardless of if the depression coincided with anxiety and/or pain. Patient status will be assessed using the Beck Depression Inventory, Beck Anxiety Inventory, and Brief Pain Inventory. Patients must have a Beck Depression Inventory score of 10 or above. These scores will be used as baseline data. Patients will be offered the option of participating in the study and provided informed consent for neuroimaging before and after the ketamine treatment.

A week before the scheduled ketamine treatment, the patients will have fMRI scans, including structural T1, Arterial Spin Labeling, and Resting BOLD. The scans take around 30 minutes at no charge to the patients. The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosages varies between 75mg - 1000mg depending on every individual's unique treatment plan. The same scans will be taken two days after treatment.

Eligibility Criteria:
Inclusion Criteria:

* In order for a subject to be considered for this study, the patient must have been diagnosed with treatment-resistant depression, meaning the patient failed three medications and has been suffering from moderate treatment-resistant depression for over 6 months, indicated by a Beck Depression Inventory score of 10 or above. The patient must have been prescribed ketamine as part of their treatment plan, completely independent of any research. The patient must be willing to comply with the study protocol.

Exclusion Criteria:

* In order for a subject to be considered for this study, he/she may not have any of the following:

  * Advanced stages of any terminal illness or any active cancer that requires chemotherapy
  * Hepatic impairment
  * Significant cytopenia
  * Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis
  * Women who are pregnant, may become pregnant, or are breastfeeding
  * Any counter indications to ketamine
  * Subjects unable to give informed consent or in vulnerable categories, such as prisoners
Hernia Surgery Urinary Retention

Investigating whether pre-operative treatment with a selective alpha1-adrenoceptor antagonist affects the likelihood of male patients developing post-operative urinary retention following hernia repair.

The purpose of this study will be to investigate whether pre-operative treatment with a selective alpha1-adrenoceptor antagonist affects the likelihood of male patients developing post-operative urinary retention following hernia repair surgery. It is also of interest to determine whether or not a well-known urological screening tool, the IPSS, can identify patients at risk for urinary retention following elective laparoscopic or open hernia repair surgery. We will investigate if it is possible to pre-treat patients with a selective alpha1-adrenoceptor antagonist which we think can reduce the incidence of post-operative urinary retention and the associated adverse consequences, especially in those patients at higher risk.

Eligibility Criteria:
Inclusion Criteria:

* Male
* 18 years of age
* Presenting with hernia requiring surgical intervention

Exclusion Criteria:

* Intolerability of tamsulosin or related drugs
* Investigator discretion
* Unwillingness or inability to comply with protocol procedures and assessments
Modafinil Effects on EEG Biomarkers of Reward and Motivation

The effects of modafinil on measures of brain electrical activity will be tested.


Eligibility Criteria:
Exclusion criteria

* history of substance abuse
* mental illness in a first degree relative
* significant medical illness (e.g. cancer, diabetes, heart disease, HIV)
* history of seizure
* open head injury or closed head injury with loss of consciousness \> 1 min
* pregnancy
* current psychotropic drug use
* R-hand injury
* hearing or visual impairment
* urine toxicology positive for recreational drug use
Study of Rivoglitazone in Type 2 Diabetes Mellitus

This is a 26-week study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo run-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of type 2 diabetes
* Male or female at least 18 years of age
* Hemoglobin A1C \> 7% and less or equal to 8.5%
* Non-fasting C-peptide \> 0.5 ng/mL
* Current monotherapy treatment with stable dose of approved non-Thiazolidinedione (TZD) antihyperglycemic medication for greater or equal to 3 months prior to screening or
* Untreated with any antihyperglycemic agent during 2 months prior to screening

Exclusion Criteria:

* History of type 1 diabetes or ketoacidosis
* History of long-term therapy with insulin
* Body Mass Index (BMI) \> 45 kg/m\^2
* Known history of Congestive Heart Failure (CHF)
* Impaired hepatic function
* History of prior treatment failure with, or intolerance of, a TZD
* Contraindication to treatment with pioglitazone
* Treatment with fibrates
* If untreated with oral antihyperglycemic, considered to have failed diet and exercise modification as the sole treatment for type 2 diabetes
Assessment of the Efficacy of Topical Curcumin in Treatment of Oral Lichen Planus

to evaluate the therapeutic impact of curcumin as Alternative or Complementary to Triamcinolone Acetonate in Treatment of Oral Lichen Planus.

Background: Oral lichen planus (OLP) is a chronic inflammatory disorder affecting the mucous membranes, believed to be an immune-mediated condition. Its persisting nature can lead to extended discomfort for those affected. The primary symptoms are pain and a burning sensation, with a potential risk of malignancy if not properly managed, necessitating lifelong clinical monitoring. Presently, OLP is considered a significant challenge due to the absence of a definitive cure.

Patients \& patients: Thirty patients with oral lichen planus were divided into three groups, 10 patients each: Group A: ten patients with OLP were received topical triamcinolone acetonide. Group B: ten patients with OLP were received topical curcumin. Group C: ten patients with oral lichen planus were received topical triamcinolone acetonide combiend with topical curcumin. For six weeks. Each patient was examined at baseline,1 and 3months of therapy. Pain was scored using the visual analogue scale. Salivary level of interleukin 1 were estimated at baseline,1and 3 months' evaluation periods.

Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of OLP

Exclusion Criteria:

* Any systemic autoimmune disease
* Any current use of anticoagulant or antiplatelet agents (curcumin has inhibitory effects on platelet aggregations).
* Any topical, local or systemic corticosteroids therapy during the past 3 months.
* lichenoid reaction from medications.
* Pregnant or lactation women.
* smokers
Effect of Travel Direction, Body Position and Technique on the Ease of Getting an Occupied Wheelchair Over a Soft Surface

Wheelchair skills training is an important step in the wheelchair provision process. Caregivers play an important role in the lives of wheelchair users but very little is known about wheelchair skills training for caregivers. The goal of the study is to understand the effect of wheelchair travel direction, wheelchair occupant body position and technique used by caregivers on the ease of getting an occupied wheelchair over a soft surface.

Able bodied participants will be used to simulate caregivers and wheelchair occupants. Participants simulating caregivers will be asked to move the occupied wheelchair over a 5 m soft surface. Participants will be randomly assigned a direction to move the wheelchair (forward or backwards), wheelchair occupant body position (upright or leaning forward) and technique in moving the wheelchair (upright with all 4 wheels on ground or in a wheelie position with the wheelchair tipped backwards and balanced on the rear wheels). The ease of getting the occupied wheelchair over the soft surface will be evaluated by the amount of time taken to complete the task, how well the participant completed the task and the ease of performing the task as evaluated by the participant.

Eligibility Criteria:
Inclusion Criteria:

* able to communicate in English,
* alert, cooperative, and competent to provide informed consent,
* willing to participate (as evidenced by attending the single data-collection session), and
* have no physical impairments that would prevent their being able to push and pull a wheelchair over a soft surface

Exclusion Criteria:

* have unstable medical conditions that might make the handling of a manual wheelchair dangerous, or emotional problems that might make participation unsafe or unpleasant.
Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

This study tests whether hydroxycitrate, a molecule closely related to citrate, can reduce calcium phosphate stone recurrence.

In this double-blind, placebo-controlled, randomized, crossover study, each participant will undergo 4 phases of study, with the order randomized by a blocked randomization scheme. The 4 phases will be Placebo, Super CitriMax (hydroxycitrate) OHCit low dose, OHCit standard dose, or Potassium Citrate. Randomization will be stratified based on sex, concomitant thiazide use, and concomitant alkali use.

Each phase will be 1 week in duration, during which subjects will take assigned study medications. A minimum 1-week washout period will be imposed between phases. During the first 2 days of each phase, subjects will be instructed to adhere to a prescribed diet. On the last 5 days of each phase, subjects will be kept on a constant metabolic diet. Use of metabolic diet is essential to eliminate confounders that could occur from changes in dietary intake across phases. During the final two study days (days 6-7), two 24-hr urines will be collected for urine biochemistry and crystallization studies. Fasting blood will be obtained at the end of the last urine collection.

Study Medications: Subjects will receive three tablets twice daily during each phase. These will consist of either placebo, Potassium Citrate (KCit), or Super CitriMax (OHCit). Study tablets will be prepared by a compounding pharmacy, with placebo tablets similar in appearance and size to the active medication tablets.

Eligibility Criteria:
Inclusion Criteria:

- Calcium Phosphate stone formers

Exclusion Criteria:

* History of recurrent urinary tract infections
* Chronic diarrhea
* Estimated Glomerular Filtration Rate (eGFR) \< 45 ml/min/1.73 m2
* History of primary hyperparathyroidism
* Hypokalemia
* Hyperkalemia
* Pregnancy
Ad Sensor-based Real-time Diagnosis of Adenovirus

To develop a real-time diagnostic technique with Ad sensor for Adenovirus detection, the investigators conduct a prospective clinical study. In comparison with results from direct sequencing of Adenovirus, the investigators evaluate the performance of Ad sensor , including reproducibility, sensitivity, specificity, and cross-reaction. The potential factors which may interfere with the results would be investigated. With such technique, the investigators hope to make early diagnosis and give Adenovirus patients early treatment to reduce the complications and case-fatality rate.

1. Sample acquirement： At National Taiwan University Hospital in Taiwan, we will enroll patients who have Adenovirus infection . We will take three throat swabs for each patient: one for viral isolation, one for RT-PCR and the last for the Ad sensor - based real-time diagnosis.
2. Ad sensor diagnosis： Ad sensor (structural chip-based optosensing virus probing system), which is for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients'and normal samples.
3. Gold standard： viral isolation and RT-PCR

Eligibility Criteria:
Inclusion Criteria:

A: The patients with confirmed or suspected infection. B: The healthy person without disease.

Exclusion Criteria:

-
Description of Changes in NIRS as a Function of Ductus Arteriosus Status in Very Premature Babies Born Before 32 WG at the DIJON University Hospital

Monitoring patent ductus arteriosus is currently performed using echocardiography, an operator-dependent examination which requires holding the child on their back and which is potentially time-consuming. This test is usually carried out on days 2, 4 and 7 after birth.

NIRS (near-infrared spectroscopy) is a non-invasive method of monitoring tissue oxygen saturation using infrared light.

The aim of the study was to investigate an association between cerebral and renal NIRS data and ductus arteriosus status obtained by echocardiography.


Eligibility Criteria:
Inclusion Criteria:

* Parent who has agreed to participate in the study
* Very premature newborn (born before 32 weeks' gestation)
* Hospitalised in the Neonatal Intensive Care Unit at Dijon University Hospital
* Before 48 hours of life

Exclusion Criteria:

* Newborn with congenital heart disease
* Newborn with a congenital renal anomaly
* Newborn with polymalformative syndrome
* Newborn with a skin anomaly
* Newborn with severe circulatory failure unrelated to the ductus arteriosus
Examination of Foot Posture's Change on Balance in Different Disorders

Foot; It is a terminal joint that opposes external resistance in the lower kinetic chain. It plays a primary role in weight transfer and ground response between the body and the ground.

To investigate the extent to which foot posture affects balance and foot function in different disease groups. The amount of studies examining the effect of the postural structure of the foot and balance seen in different disease groups in the literature is insufficient.

Eligibility Criteria:
Inclusion criteria;

* Being between the ages of 45 - 65,
* Volunteer. Exclusion criteria;
* Having a musculoskeletal or neuromuscular disease that limits mobility,
* Presence of lower extremity sequelae,
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting the grade 3 tumors based on the novel grading system in clinical stage stage I lung adenocarcinoma based on a multicenter prospective cohort.


Eligibility Criteria:
Inclusion Criteria:

(1) Participants scheduled for surgery for radiological finding of pulmonary lesions from the preoperative thin-section CT scans; (2) The maximum diameter of lesion less than 4 cm on CT scans; (3) The maximum short axis diameter of lymph nodes less than 1 cm on CT scan; (4) The SUVmax of hilar and mediastinal lymph nodes less than 2.5; (5) Pathological confirmation of primary lung adenocarcinoma; (5) Age ranging from 20-75 years; (6) Obtained written informed consent.

Exclusion Criteria:

(1) Multiple lung lesions; (2) Poor quality of PET-CT images; (3) Participants with incomplete clinical information; (4) Mucinous adenocarcinomas; (5) Participants who have received neoadjuvant therapy.